aTyr Pharma Inc (LIFE)

3.55
0.05 1.43
NASDAQ : Health Care
Prev Close 3.50
Open 3.48
Day Low/High 3.42 / 3.55
52 Wk Low/High 2.48 / 21.00
Volume 26.65K
Avg Volume 233.40K
Exchange NASDAQ
Shares Outstanding 23.75M
Market Cap 81.93M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ATyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris™ In Exploratory Trials

ATyr Pharma Reports Promising Signals Of Clinical Activity In Multiple Rare Genetically Distinct Myopathies With Resolaris™ In Exploratory Trials

- Improved Muscle Strength Observed in 50% to 78% of Patients in Two Rare Genetically Distinct Myopathies -

ATyr Pharma Receives FDA Fast Track Designation For Resolaris™ To Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

ATyr Pharma Receives FDA Fast Track Designation For Resolaris™ To Treat Facioscapulohumeral Muscular Dystrophy (FSHD)

-- First Reported Fast Track Designation for a FSHD Treatment --

7 Stocks Under $10 Making Big Moves Higher

7 Stocks Under $10 Making Big Moves Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

These 5 Stocks Are Breaking Out

These 5 Stocks Are Breaking Out

Here's a technical look at how to trade five stocks that are within range of triggering big breakouts.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

Here’s A Reason aTyr Pharma (LIFE) Stock is Rising Today

Here’s A Reason aTyr Pharma (LIFE) Stock is Rising Today

Shares of aTyr Pharma (LIFE) are climbing late Tuesday afternoon as BMO Capital began coverage of the stock with a ‘market perform’ rating and $8 price target.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

ATyr Provides Corporate Update And Outlook For 2016

ATyr Provides Corporate Update And Outlook For 2016

Data for Phase 1b/2 Clinical Trial of Resolaris in Adult FSHD Patients Expected at Approximately the End of First Quarter 2016